C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Net Cash Flow of -$13.3 million for Q1 2026, down 216.9% year-over-year from $11.4 million in Q1 2025, and down 184.39% quarter-over-quarter from $15.8 million in Q4 2025.
C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2026) Analysis & Trends
C4 Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$13.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 216.9% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at $10.0 million (up 126.02% YoY), while the FY2025 annual figure was $19.1 million, up 126.87% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$13.3 million, down from $15.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $65.6 million in Q4 2023, with the low at -$36.9 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$4.6 million (2023), against an average of -$863882.4.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow sank 287.26% in 2024, then soared 480.58% in 2025.
- C4 Therapeutics' Net Cash Flow stood at -$19.8 million in 2022, then soared by 431.4% to $65.6 million in 2023, then plunged by 106.33% to -$4.1 million in 2024, then jumped by 480.58% to $15.8 million in 2025, then tumbled by 184.39% to -$13.3 million in 2026.
- Business Quant data shows CCCC's Net Cash Flow at -$13.3 million in Q1 2026, $15.8 million in Q4 2025, and -$19.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 17.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.34 Mn |
| Jun 30, 2026 | 17.34 Mn |
| Mar 31, 2026 | -13.33 Mn |
| Mar 31, 2026 | -13.33 Mn |
| Dec 31, 2025 | 15.79 Mn |
| Dec 31, 2025 | 15.79 Mn |
| Sep 30, 2025 | -19.35 Mn |
| Sep 30, 2025 | -19.35 Mn |
| Jun 30, 2025 | 26.86 Mn |
| Jun 30, 2025 | 26.86 Mn |
| Mar 31, 2025 | -4.21 Mn |
| Mar 31, 2025 | -4.21 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Sep 30, 2024 | -13.47 Mn |
| Sep 30, 2024 | -13.47 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Mar 31, 2024 | -36.93 Mn |
| Mar 31, 2024 | -36.93 Mn |